# **Biological function of a polysaccharide degrading enzyme in the periplasm**

Yajie Wang $^1$ , M. Fata Moradali $^1$ , Ali Goudarztalejerdi $^3$ , Ian M. Sims $^4$ , Bernd H. A. Rehm $^{1,2^*}$ 

Affiliations

 $1$ Institute of Fundamental Sciences, Massey University, Palmerston North, New Zealand

<sup>2</sup> MacDiarmid Institute for Advanced Materials and Nanotechnology, Massey University, Palmerston North, New Zealand

<sup>3</sup> Department of Pathobiology, School of Paraveterinary Science, Bu-Ali Sina University, Hamadan, Iran

<sup>4</sup>The Ferrier Research Institute, Victoria University of Wellington, Lower Hutt, Wellington, New Zealand

\* [B.Rehm@massey.ac.nz](mailto:B.Rehm@massey.ac.nz) (Institute of Fundamental Sciences and MacDiarmid Institute for Advanced Materials and Nanotechnology, Massey University, Private Bag 11222, Palmerston North 4442, New Zealand)

# **Supplementary Methods**

# **Generation and confirmation of** *algL* **mutant**

To generate an isogenic marker-free PDO300Δ*algL* mutant, the gene-replacement plasmid pEX100TΔ*algLΩGm<sup>R</sup>* was constructed and introduced into *P. aeruginosa* PDO300 (Figure S1). To construct this plasmid, two regions of the *algL* gene were synthesized. These regions algLN and algLC were 352 and 449 bp in length, and corresponded to nucleotides 12-363 and 644-1093 bp of *algL* ORF. At the 3' end of algLN and at the 5' end of algLC, *Bam*HI restriction sites were introduced. These DNA fragments were digested with *Bam*HI and then ligated with a FRT-*aacC1*-FRT cassette (a 1,100 bp *Bam*HI fragment from pPS856) into *Sma*I (a blunt-cutter) linearized pEX100T plasmid yielding pEX100TΔ*algLΩGm<sup>R</sup>* . (FRT = flip-recombinase recognition sites; *aacC1* = a gentamycin resistance marker). pEX100TΔ*algLΩGm<sup>R</sup>*was introduced into *P. aeruginosa* PDO300 by transconjugation. Integration of gentamycin resistance marker and subsequent deletion of 280 bp of *algL* open reading frame (ORF) was verified by PCR using primers algLupXout and algLdownXout.

#### **Manipulation of DNA**

Deoxynucleoside triphosphates, Taq, and Platinum Pfx polymerases were from Invitrogen. Restriction enzymes were from New England Biolabs. DNA was cloned using CloneJET PCR Cloning kit (Thermo Scientific, USA). DNA was verified by sequencing using an ABI310 automatic sequencer.

### **Isolation of envelope fraction**

Envelope fractions were isolated <sup>[1](#page-12-0)</sup>. Cells were lysed by lysozyme treatment (for 20 min on ice in 100 mM phosphate buffer, pH 7.5, 150 mM NaCl, 0.1 mg/mL of lysozyme and 0.1 mg/ml of DNAase I) followed by sonication. Cell debris was removed (15,000 g for 45 min at 4 °C) and envelope fractions were sedimented (100,000 g for 90 min at 4 °C).

# **Crystal violet staining**

To each well of microtitre plate, 150 μL of crystal violet solution (0.1% w/v in water) was added and then incubated for 10 min. Unbound stain was removed by washing with water. Plates were dried and bound crystal violet was solubilized in 200 μL of DMSO and absorbance at 595 nm was measured.



**Figure S1. Generation and confirmation of PDO300Δ***algL* **and its complemented strain** (**a**) A schematic detailing the generation and confirmation of PDO300Δ*algL* mutant. To generate PDO300Δ*algL*, a gene replacement plasmid pEX100TΔ*algL*Gm was constructed and introduced into PDO300 for homologous recombination, replacing 281 bp of *algL* gene with an FRT-*aacC1*-FRT cassette. This cassette contains a gentamycin resistance marker (*aacC1*) flanked by flp-recombinase recognition sites (FRT). A flp-recombinase encoding plasmid, pFLP2,was introduced to remove the FRT-*aacC1*-FRT cassette. Excision of the cassette and deletion of 281 bp of *algL* gene (Red Rectangle) in the PDO300Δ*algL* mutant was confirmed by colony PCR. (**b**) PDO300 and PDO300Δ*algL* were confirmed by colony PCR using primers algLupXout and algLdownXout which flank the *algL* gene in the chromosome. PCR products were subject to agarose gel electrophoresis and stained by ethidium bromide. PCR products from PDO300 (Lane 1, WT) and PDO300Δ*algL* (Lane 3, dL) are shown at expected molecular weights of 1,465 and 1,349 bp, respectively. Lane 2 = DNA MW Ladder (mw). (**c**) Immunoblot of envelope fractions to verify the absence and presence of AlgL protein in the *algL* mutant (PDO300Δ*algL*(pHERD20T)] and its complemented strain (PDO300Δ*algL*(pHERD20T:*algL*)] when grown on PIA containing Carbenicillin (300 μg/ml) and arabinose (0.5% w/v).



**Figure S2. Alginate lyase assay of strains grown on solid media.** Strains were grown in presence of 0.5% (w/v) arabinose on PIA (72 h) medium containing Carbenicillin (300 μg/ml). Biomass of biofilms was re-suspended in saline and then filter-sterilized. 100 μL of cell-free resuspensions were dropped onto alginase assay plates and incubated for 24 h at 37 °C. Plates were flooded with 10 % w/v cetylpyridinium chloride for overnight incubation. Clearings are indicative of alginate degradation. Commercial alginate lyase (Sigma Aldrich, USA) and autoclaved saline were used as positive (+) and negative (-) controls. Strains identified as follows: ΔalgL = PDO300Δ*algL*(pHERD20T), and ΔalgL+algL = PDO300Δ*algL*(pHERD20T:*algL*).



**Figure S3. Full length immunoblots for detection of components of the alginate biosynthesis apparatus in various** *alg* **mutants.** Shown are immunoblots of envelope fractions of various strains using anti-Alg antibodies (*from left*: α-Alg44, α-AlgK, α-AlgX, α-AlgE and α-AlgL) to detect specific components of biosynthesis complex. Red arrows highlight target proteins at expected molecular weight. Strains are identified as follows: Δalg44 = PDO300Δ*alg44*, ΔalgK = PDO300Δ*algK*, ΔalgX = PDO300Δ*algX*, ΔalgE = PDO300Δ*algE*, ΔalgL = PDO300Δ*algL*, and WT = *P. aeruginosa* PDO300. MW markers are shown in kDa.



1 2 3 4 5 lane

**Figure S4. Full length immunoblots showing the detection of hexahistidine-tagged AlgL and its interaction partners.** Strains were grown on PIA medium supplemented with 300 μg/ml of Carbenicillin (except for PDO300*algL*, lane 1) and 0.05% (w/v) arabinose for 72 h at 37 °C. Envelope (E) fractions were prepared and histagged-AlgL and its co-interacting proteins were purified with c0mplete His-Tag Purification Resin (Roche). Envelope (E) and eluted (Elu.) fractions were run on SDS-PAGE, transferred to nitrocellulose membrane and subject to immunoblot with various antibodies (*identified above each panel*: α-Alg44, α-AlgK, α-AlgG, α-AlgX and α-Histag), as described in methods section. In each panel, Lane 1 = Envelope fraction of PDO300Δ*algL*. Lanes 2 and 3 = Envelope (E) and eluted (Elu.) fractions of PDO300Δ*algL*(pHERD20T:*algL*), respectively. Lanes 4 and 5 = Envelope (E) and eluted (Elu.) fractions of PDO300Δ*algL*(pHERD20T *algLx6his*), respectively.



Figure S5. Effect of alginate O-acetylation on cell attachment, biofilm biomass and dispersal efficiency. Attachment efficiencies, biofilm biomasses and dispersal efficiencies were analyzed in a microtiter plate assay. (**a**) Mean attachment efficiencies ± SE (n =6) at 2 h, as determined by crystal violet staining. Attachment efficiencies are expressed as absorbances at 595 nm. (**b**) Mean biomass of biofilms ± SE (n =4) at 72 h, as determined by crystal violet staining. (c) Mean dispersal efficiencies ± SE (n=6) at 72 h expressed as colony forming units (CFU x 10<sup>4</sup>). In panels (a), (b) and (c) different letters displayed above columns indicate statistically significant differences (two-way, t-test, p < 0.05) in attachment efficiency, biofilm biomass and dispersal efficiency, respectively. In panels (**a**), (**b**) and (**c**), strains ΔalgX+algX and ΔalgL+algXS269A are identified as PDO300Δ*algX*(pBBR1MCS-5:*algX*) and PDO300Δ*algX*(pBBR1MCS-5:*algXS269A*), respectively. These strains produce O-acetylated and non-acetylated forms of alginate, respectively.



**Table S1. Strains, plasmids and oligonucleotides used in this study.**

# **Supplementary References**

- <span id="page-12-0"></span>1 Wang, Y., Hay, I. D., Rehman, Z. U. & Rehm, B. H. A. Membrane-anchored MucR mediates nitrate-dependent regulation of alginate production in *Pseudomonas aeruginosa*. *Appl. Microbiol.Biotechnol.* **99**, 7253-7265 (2015).
- <span id="page-12-1"></span>2 Mathee, K. *et al.* Mucoid conversion of *Pseudomonas aeruginosa* by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. *Microbiology-Sgm* **145**, 1349-1357 (1999).
- <span id="page-12-2"></span>3 Remminghorst, U. & Rehm, B. H. A. Alg44, a unique protein required for alginate biosynthesis in *Pseudomonas aeruginosa*. *Febs Lett.* **580**, 3883- 3888 (2006).
- <span id="page-12-3"></span>4 Rehman, Z. U., Wang, Y. J., Moradali, M. F., Hay, I. D. & Rehm, B. H. A. Insights into the assembly of the alginate biosynthesis machinery in *Pseudomonas aeruginosa*. *Appl. Environ. Microbiol.* **79**, 3264-3272 (2013).
- <span id="page-12-4"></span>5 Gutsche, J., Remminghorst, U. & Rehm, B. H. A. Biochemical analysis of alginate biosynthesis protein AlgX from *Pseudomonas aeruginosa*: purification of an AlgX-MucD (AlgY) protein complex. *Biochimie* **88**, 245-251 (2006).
- <span id="page-12-5"></span>6 Hay, I. D., Rehman, Z. U. & Rehm, B. H. A. Membrane topology of outer membrane protein AlgE, which is required for alginate production in *Pseudomonas aeruginosa*. *Appl. Environ. Microbiol.* **76**, 1806-1812 (2010).
- <span id="page-12-6"></span>7 Qiu, D., Damron, F. H., Mima, T., Schweizer, H. P. & Yu, H. D. P-BAD-based shuttle vectors for functional analysis of toxic and highly regulated genes in *Pseudomonas* and *Burkholderia* spp. and other bacteria. *Appl. Environ. Microbiol.* **74**, 7422-7426 (2008).